Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a vitamin pill slow Parkinson's? major trial tests nicotinamide riboside

NCT ID NCT03568968

Disease control Sponsor: Haukeland University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 3 trial tested whether a daily supplement called nicotinamide riboside (a form of vitamin B3) can slow the progression of early Parkinson's disease. 410 people with early-stage Parkinson's took either the supplement or a placebo for 52 weeks. Researchers measured changes in motor and non-motor symptoms using a standard rating scale. The goal was to see if replenishing a key cellular energy molecule (NAD) could help protect brain cells.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nicotinamide riboside (a form of vitamin B3)
What this could lead to
If it works, this could point toward a way to slow the progression of early Parkinson's disease using a simple dietary supplement.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The supplement may not slow the disease, and benefits may be small or not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

410 people

The number who actually took part.

Started

May 2020

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a clinical diagnosis of idiopathic PD according to the MDS clinical diagnostic criteria for Parkinson's disease * \[¹²³I\]FP-CIT single photon emission CT (DaTscan) confirming nigrostriatal degeneration * Diagnosed with PD within 2 years from enrolment * Hoehn and Yahr score \< 3 at enrolment * Optimal symptomatic therapy, not requiring adjustments, for at least 1 month. * Age equal to or greater than 35 years at time of enrolment. Exclusion Criteria: * Dementia or other neurodegenerative disorder at baseline visit * Diagnosed with atypical parkinsonism or vascular parkinsonism * Any psychiatric disorder that would interfere with compliance in the study. * Any severe somatic illness that would make the individual unable to comply and participate in the study. * Use of high dose vitamin B3 supplementation within 30 days of enrolment * Metabolic, neoplastic, or other physically or mentally debilitating disorder at baseline visit. * Genetically confirmed mitochondrial disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease

Contacts and locations

Locations

  • Akershus university hospital

    Oslo, Norway

  • Arendal Hospital

    Arendal, Norway

  • Bodø Hospital

    Bodø, Nordland, Norway

  • Førde sykehus

    Førde, Norway

  • Haugesund Hospital

    Haugesund, Norway

  • Haukeland University Hospital

    Bergen, Norway

  • Molde sjukehus

    Molde, Norway

  • Oslo University Hospital

    Oslo, Norway

  • University Hospital of North Norway

    Tromsø, Norway

  • Vestre Viken Hospital

    Drammen, Norway

  • Østfold Hospital

    Fredrikstad, Østland, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.